Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
GeneDx Holdings Corp.
WGS
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $2.1B
$67.98
▼ -5.20%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$32.21 - $170.87
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 20.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI/ML algorithms analyzing integrated genomic and clinical data
- Founder expertise: Eric Schadt is a pioneering figure in systems genetics and precision medicine
- Centrellis platform creates defensible data moat with longitudinal patient insights
- Patient-centric approach differentiates from competitor-focused models
Bear Case
2 risks
- Above-average volatility (beta 2.0).
- Extreme premium - high expectations embedded
Growth
Turning profitable
Expanding adoption of precision medicine and genomic testing in clinical practice
Value
Extreme premium - high expectations embedded
Momentum
Strong
+8.3% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying WGS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 28, 2026
MAY 4, 2026
Reported EPS of -$0.28 vs -$0.06 consensus (-366.7% surprise). Revenue of $102.3M vs $112.5M expected (-9.1%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-366.7%
Next: Apr 28, 2026
Revenue trend · last 8Q
—
—
+67%
+40%
+46%
+52%
+27%
+17%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$70.5M
$76.9M
$95.6M
$87.1M
$102.7M
$116.7M
$121.0M
$102.3M
Margins · last 8Q
Gross
—
Operating
—
Profit
-61.9%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$75.00
▲ +10.3% vs $67.98
Latest: Guggenheim · $74.00 · Jun 29, 2026
5 analysts covering